A Study of LUMIGAN® RC in the Clinical Setting

• Status: Completed
• Trial end date: 2011-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate bimatoprost 0.01% (LUMIGAN® RC) in patients with elevated intraocular pressure (IOP) due to primary open angle glaucoma (POAG) or ocular hypertension (OHT) in a clinical setting.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Bimatoprost

Criteria

Inclusion Criteria:

• Elevated IOP due to either primary open-angle glaucoma or ocular hypertension

• Determined by the treating physician to require treatment with LUMIGAN® RC

Exclusion Criteria:

• None